TickerTalks
Browse all tickers →
TickerTalks›$AFJK
AFAFJK

Aimei Health Technology Co., Ltd

$AFJK·$75M·Shell Companies·Financial Services
$12.09-0.1%YTD-85.9%1Y+7.1%
Mentions · last 7 days
2026-08-21: 1 posts2026-08-22: 0 posts2026-08-23: 0 posts2026-08-24: 0 posts50%
Price updated 14m ago·X counts updated 7d ago
AFAFJK
$AFJKAimei Health Technology Co., Ltd
$12.09-0.08%5 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AFJK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-21

Falling on heavy selling — points lower unless it turns around.

SPAC with a terminated deal, Nasdaq delinquency notice, and a shrinking runway — the story is closer to closure than to a new target.

Aimei Health Technology is a shell company that was structured to acquire a biopharma, medtech, or diagnostic target. The story ended when the United Hydrogen Group business-combination agreement was terminated on July 7 after 20 trust-extension payments, leaving the shell without a deal and with a tightening clock.

  • The equity is down 86% year-to-date and sits at the 5th percentile of the 52-week range — the tape has priced in the deal collapse, and there is no announced replacement.
  • Volume is 88% below the 30-day average — the marginal holder is not trading, which is what a post-termination SPAC with no target looks like when it is drifting toward wind-down.
  • Received a Nasdaq notice on May 20 regarding a delayed quarterly report — the exchange-compliance overhang is a second concurrent problem on top of the terminated deal.
  • Filed an 8-K on Aug 6 disclosing a new financial obligation of $0.0001 (a nominal note extension typical of SPACs buying time) — the structure is looking for a landing rather than pursuing a new operating combination.

What changes the picture is a specific announcement of a new business-combination target in a fundable sector. What confirms the breaking-down path is another Nasdaq-compliance escalation, a trust-liquidation vote, or another deal termination if a new target is later named; treat this as a wind-down candidate until a real target emerges.

What to watch: Any 8-K announcing a new merger target, a trust extension vote, or a Nasdaq deficiency escalation. Watch the trust-value versus stock-price relationship for arbitrage indicators.

On the calendar: Next Nasdaq compliance deadline — not yet disclosed

Read the AI verdict + X sentiment for $AFJK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Blank-check SPAC seeking acquisitions in biopharmaceuticals, medical devices, and diagnostics; no operating business yet.

Industry overviewAI analysisGenerated by AI from underlying data

Where Shell Companies sits in its cycle right now — and what that implies for $AFJK.

Shell Companies · Financial Services

SPAC and blank-check vehicles are driven by the M&A and deal environment; sponsor pipeline quality varies widely, making individual-name due diligence critical. The structural de-SPACing overhang from the 2020-21 vintage continues to weigh on the category.

What this means for $AFJK

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; Aimei Health Technology Co.

Industry benchmark

5-name peer basket
-21.0%YTD
+60.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
75.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-4.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.03——
Q1 2026Jun 16, 2026$0.01——
Q3 2025Nov 18, 2025$0.06——
Q2 2025Aug 13, 2025$0.07——

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$0.01$-75K
Q4 FY25$0———$0.02$-43K
Q3 FY25$0———$0.06$-96K
Q2 FY25$0———$0.07$-202K

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.4%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-26.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-63.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 1.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.555-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KListing / delisting noticeAug 258-K — Item 3.01: Listing / delisting notice
AI summary

Aimei Health Technology Co., Ltd. (AFJK) received a notice from Nasdaq's Listing Qualifications Department on August 21, 2026, stating that the company's Market Value of Listed Securities (MVLS) has been below the $50 million minimum required for continued listing on The Nasdaq Global Market for the last 30 consecutive business days. The company's ordinary shares, rights, and units are all listed on Nasdaq. Nasdaq typically grants a 180-calendar-day grace period to regain compliance. This is a material delisting risk signal; failure to restore MVLS above $50M within the cure period could result in delisting proceedings for all three security classes.

8-KMaterial debt obligationAug 68-K — Item 2.03: Material debt obligation
AI summary

AFJK filed an 8-K (Item 2.03) disclosing creation of a direct financial obligation of $0.0001 . New debt obligations are material and may affect leverage ratios and credit metrics.

8-KAgreement terminatedJul 88-K — Item 1.02: Agreement terminated · Item 7.01: Press release / Reg FD
AI summary

Aimei Health Technology Co., Ltd (AFJK) terminated its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, delivering a notice of termination to the target effective the same day. The agreement, originally signed June 19, 2024 and amended June 6, 2025, covered a multi-entity combination involving United Hydrogen and several affiliated Cayman Islands entities. The proposed business combination will not be consummated. This is highly material for AFJK shareholders: the SPAC has now lost its merger target after 20 trust extension payments, leaving the company without a deal and facing a narrowing window to find a new target.

8-KMaterial debt obligationJul 68-K — Item 2.03: Material debt obligation
AI summary

Aimei Health Technology (AFJK) made its 20th consecutive one-month SPAC extension on July 6, 2026, depositing $34,330.96 into the trust account to push the termination date from July 6 to August 6, 2026. The company issued an unsecured, zero-interest promissory note of $34,330.96 to Aimei Health Ltd, convertible at the holder's option into private units at $10.00 per unit, due upon business combination close. This extension was made while merger termination proceedings were already in motion — the United Hydrogen deal was terminated the very next day — making it effectively the SPAC's final extension before losing its target.

3New insider — initial holdingsJul 13
AI summary

Form 3 initial statement of beneficial ownership filed on July 1, 2026 by Daniel Veikko Polvi, newly appointed director of Aimei Health Technology Co. (AFJK), with an event date of June 29, 2026. Polvi is identified as both a Director and a 10% Owner. No securities are reported as beneficially owned in the filing. This is a routine Section 16 insider-reporting obligation accompanying a board appointment.

8-KOfficer or director changeJun 298-K — Item 5.02: Officer or director change
AI summary

Aimei Health Technology (AFJK) reported two director changes on June 29, 2026: Julianne Huh resigned effective June 24, 2026 citing personal reasons with no company disagreement, and Daniel Veikko Polvi was appointed as her replacement effective June 29, 2026. Polvi holds an MBA from BI Norwegian Business School (2018) and has served as Managing Director of Shearwater Limited, an international management consulting firm, since May 2019. This is a routine board personnel change with no stated strategic significance.

8-KMaterial debt obligationJun 48-K — Item 2.03: Material debt obligation
AI summary

Aimei Health Technology (AFJK) made its 19th SPAC extension on June 4, 2026, depositing $34,330.96 into the trust account to push the termination date from June 6 to July 6, 2026. The corresponding promissory note of $34,330.96 was co-issued to Aimei Health Ltd and United Hydrogen Group Inc. ($17,165.48 each), bearing no interest and convertible into private units at $10.00/unit. This is the penultimate extension before the deal was ultimately terminated in July 2026, signaling persistent delays in completing the United Hydrogen combination.

8-KListing / delisting noticeMay 208-K — Item 3.01: Listing / delisting notice
AI summary

Aimei Health Technology (AFJK) received a Nasdaq delisting notice on May 19, 2026 for failing to timely file its Form 10-Q for Q1 2026 (period ending March 31, 2026; due May 15, 2026), violating Nasdaq Listing Rule 5250(c)(1). The company has 60 calendar days to file the overdue 10-Q or submit a compliance plan; if accepted, up to 180 days total from the original due date to regain compliance. Combined with 20 SPAC trust extensions and the subsequent termination of its United Hydrogen merger target, this delisting notice is a significant additional negative for AFJK shareholders.

+ 10 other (4 8-Ks · 2 10-Qs · 2 13Gs · 1 10-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Aimei Health Technology (NASDAQ:AFJK) Shares Up 0.4% – Here’s What Happeneddefenseworld.net·20d agoAIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC.globenewswire.com·54d agoAIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC.globenewswire.com·54d ago

More in Shell Companies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$RFAI$CCXI$RDAC$FVN$RACC$DAAQ$FGMC$TCGX
Voices on X · last 7 days

No standout posts about $AFJK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport